The overall goals of the Cancer Molecular Therapeutics (CMT) Program (formerly Aging, Cancer and Immuno-oncology (ACI)) are to engage active collaborations among members of the program to enable new research initiatives and grant programs that will define how the interplay among cancer cells, immune cells, stromal components, and vasculature regulates the growth and metastasis of solid and hematologic malignancies, and to use this knowledge to discover new, more effective cancer treatments.